Filing Flows › Pulmonx (LUNG) › Q3 2026
Pulmonx (LUNG) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Pulmonx (LUNG) reported revenue of $22.8M for the third quarter 2026 (Q3 2026), +6% from a year earlier and +0.3% from the quarter before. Operating margin was -32.8%, net loss $8.4M (36.8% of revenue).
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.8M | +0.3% | +6% |
| Operating profit | −$7.5M | — | — |
| Net earnings | −$8.4M | — | — |
| Operating cash flow | −$3.2M | — | — |
What changed
Revenue was $22.8M in Q3 2026, up 6% year over year and roughly flat from the previous quarter.
Gross margin was 76.2%, up 1.5 points from Q3 2025. Operating costs exceeded revenue by $7.5M, an operating margin of -32.8%. Operating expenses fell 18% while revenue rose 6%. The quarter ended with a net loss of $8.4M, narrower than the previous quarter's $10.1M loss.
Operating cash flow was −$3.2M. Non-cash charges added back $200K of depreciation and $3.6M of share-based compensation. Working capital and other items added $1.4M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$3.2M.
Questions
What was Pulmonx's revenue in the third quarter 2026?
Pulmonx (LUNG) reported revenue of $22.8M for the third quarter 2026 (Q3 2026), +6% from a year earlier and +0.3% from the quarter before.
Was Pulmonx profitable in the third quarter 2026?
Operating loss was $7.5M (-32.8% of revenue) and net loss $8.4M.
Source: Pulmonx 10-Q on SEC EDGAR.